Ratings for Immunocore Hldgs IMCR were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 7 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $86.44, a high estimate of $100.00, and a low estimate of $66.00. This current average represents a 0.77% decrease from the previous average price target of $87.11.
Understanding Analyst Ratings: A Comprehensive Breakdown
The analysis of recent analyst actions sheds light on the perception of Immunocore Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gil Blum | Needham | Maintains | Buy | $81.00 | $81.00 |
| Jessica Fye | JP Morgan | Lowers | Overweight | $66.00 | $70.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $100.00 | $100.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | $81.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $100.00 | $100.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | $81.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $100.00 | $100.00 |
| Gil Blum | Needham | Maintains | Buy | $81.00 | $81.00 |
| Graig Suvannavejh | Mizuho | Lowers | Buy | $88.00 | $90.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Immunocore Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Immunocore Hldgs compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Immunocore Hldgs's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Immunocore Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Immunocore Hldgs analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Immunocore Hldgs
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
Financial Insights: Immunocore Hldgs
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Immunocore Hldgs displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 28.99%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Immunocore Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -34.66%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Immunocore Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -6.71%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Immunocore Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of -3.07%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Immunocore Hldgs's debt-to-equity ratio surpasses industry norms, standing at 1.31. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
